skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Sister chromatid exchange induction in patients with anaplastic gliomas undergoing treatment with radiation plus diaziquone or 1,3-bis(2-chloroethyl)-1-nitrosourea

Journal Article · · Cancer Res.; (United States)
OSTI ID:6789848

Diaziquone (AZQ) (NSC 182986), a lipid-soluble benzoquinone derivative, is presently being tested in a Phase III clinical trial to determine its efficacy in patients with anaplastic gliomas compared to the more standard 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) treatment following whole-brain irradiation. These patients on single-drug chemotherapy allowed us to evaluate the effects of each agent on sister chromatid exchange (SCE) induction in vivo. Eight weeks following the final radiation treatment, patients were randomly assigned to one of two groups: (a) 200 mg BCNU/m2, i.v., every 8 weeks; of (b) 15 mg AZQ/m2/day, i.v., for 3 consecutive days, every 4 weeks. Blood (5-10 ml) was drawn by venipuncture before treatment, within 10 h after treatment, and for two BCNU-treated patients at various other times. Peripheral blood lymphocytes were cultured by standard techniques for analysis of SCE. Eight weeks after irradiation but before chemotherapy, the mean SCE frequency in the patients' peripheral blood lymphocytes was 9.6 SCEs/metaphase. Following treatment with AZQ or BCNU, the baseline SCE frequency was increased more than 2-fold or 3-fold, respectively. Two months after BCNU treatment, there was less than a 25% reduction in SCE levels compared to samples taken and cultured within 10 h after treatment. These data show that lesions leading to SCE in human peripheral blood lymphocytes are relatively longlived, and that on a mg/m2 basis, AZQ is a more potent inducer of SCE in vivo than is BCNU.

Research Organization:
Environmental Health Research and Testing, Inc., Research Triangle Park, NC
OSTI ID:
6789848
Journal Information:
Cancer Res.; (United States), Vol. 2
Country of Publication:
United States
Language:
English

Similar Records

Hyperfractionated radiaton therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma - possible advantage observed at 72. 0 Gy in 1. 2 Gy B. I. D. fractions: Report of the radiation therapy oncology group protocol 8302
Journal Article · Fri Jan 15 00:00:00 EST 1993 · International Journal of Radiation Oncology, Biology and Physics; (United States) · OSTI ID:6789848

Persistence of SCE-inducing lesions in lymphocytes of mice exposed to diaziquone
Journal Article · Fri Jan 01 00:00:00 EST 1988 · Environ. Mol. Mutagen.; (United States) · OSTI ID:6789848

Immunologic monitoring of patients with small cell anaplastic carcinoma who are treated with chemotherapy and radiotherapy
Journal Article · Fri Aug 01 00:00:00 EDT 1980 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:6789848